RE:RE:RE:Takeover/BuyoutAny buyout in the $1.50 to $2.00 range hostile or not would be met with competing offers. Does anyone think that if Company X made that offer the rest of the pharma world would sit there and say "it's yours"? But we are way too early for all this talk because it's impossible to put a fair value on anything but NMIBC, let's at least wait until they start trials on GBM and NSCLC then there's the viruses. I don't think we need to be worried about be low balled.